Yahoo Finance Trade Alert: The Chairman & CEO Of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX), Anthony Mack, Has Just Spent US$100k Buying 17% More Shares
Investors who take an interest in Virpax Pharmaceuticals, Inc. ( NASDAQ:VRPX ) should definitely note that the Chairman & CEO, Anthony Mack, recently paid US$3.99 per share to buy US$100k worth of the stock. That's a very solid buy in our book, and increased their holding by a noteworthy 17%.
View our latest analysis for Virpax Pharmaceuticals
The Last 12 Months Of Insider Transactions At Virpax Pharmaceuticals
Notably, that recent purchase by Anthony Mack is the biggest insider purchase of Virpax Pharmaceuticals shares that we've seen in the last year. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$4.45. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.
Virpax Pharmaceuticals insiders may have bought shares in the last year, but they didn't sell any. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
Virpax Pharmaceuticals is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.
Does Virpax Pharmaceuticals Boast High Insider Ownership?
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. Based on our data, Virpax Pharmaceuticals insiders have about 27% of the stock. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. I generally like to see higher levels of ownership.
What Might The Insider Transactions At Virpax Pharmaceuticals Tell Us?
It is good to see recent purchasing. And an analysis of the transactions over the last year also gives us confidence. But we don't feel the same about the fact the company is making losses. While the overall levels of insider ownership are below what we'd like to see, the history of transactions imply that Virpax Pharmaceuticals insiders are reasonably well aligned, and optimistic for the future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Virpax Pharmaceuticals. Case in point: We've spotted 3 warning signs for Virpax Pharmaceuticals you should be aware of, and 1 of these can't be ignored.
But note: Virpax Pharmaceuticals may not be the best stock to buy . So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
